Foscarnet
Antona J. Wagstaff, Harriet M. Bryson · Drugs · 1994
Cited by 232 works. doi:10.2165/00003495-199448020-00007
Authors
References
- A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow Transplants
- Early Treatment with Ganciclovir to Prevent Cytomegalovirus Disease after Allogeneic Bone Marrow Transplantation
- INHIBITION OF HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE III IN VITRO BY PHOSPHONOFORMATE
- Mortality in Patients with the Acquired Immunodeficiency Syndrome Treated with either Foscarnet or Ganciclovir for Cytomegalovirus Retinitis
- Treatment of Cytomegalovirus Pneumonia with Ganciclovir and Intravenous Cytomegalovirus Immunoglobulin in Patients with Bone Marrow Transplants
- Cytomegalovirus Pneumonia after Bone Marrow Transplantation Successfully Treated with the Combination of Ganciclovir and High-Dose Intravenous Immune Globulin
- Incidence and Natural History of Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine
- Acyclovir-Resistant Herpes Simplex Virus Infections in Patients with the Acquired Immunodeficiency Syndrome
- Antiviral effects of phosphonoformate (PFA, foscarnet sodium)
- Cytomegalovirus Excretion as a Predictor of Cytomegalovirus Disease after Marrow Transplantation: Importance of Cytomegalovirus Viremia